Mochi Health Prescribing Data and Outcomes Signals: An Independent Review

What Is Mochi Health and How Does Its Prescribing Model Work?

Mochi Health operates as a direct-to-consumer telehealth company focused on obesity medicine. Providers on the platform can prescribe FDA-approved GLP-1 receptor agonists as well as compounded versions when branded drugs are unavailable due to shortage. The company accepts some commercial insurance and also offers cash-pay pricing, which makes it accessible to patients who cannot get coverage.

The Two Prescribing Pathways

The insurance pathway routes patients toward FDA-approved branded medications. Semaglutide 2.4 mg (Wegovy) and tirzepatide 15 mg (Zepbound) both carry FDA approval specifically for chronic weight management, with approval based on BMI ≥30 or BMI ≥27 plus at least one comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. [1] The FDA label for Wegovy was granted in June 2021 following the STEP program, where STEP-1 (N=1,961) demonstrated 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (P<0.001). [2]

The cash-pay pathway has included compounded semaglutide and compounded tirzepatide sourced from 503B outsourcing facilities or 503A pharmacies. This distinction matters clinically. In October 2024, the FDA declared the semaglutide shortage resolved, triggering restrictions on compounding. [3] Platforms continuing to dispense compounded semaglutide after that date face regulatory scrutiny.

What the Prescribing Eligibility Criteria Should Look Like

Standard-of-care prescribing for GLP-1 agonists in obesity follows the 2023 American Association of Clinical Endocrinology (AACE) Obesity Clinical Practice Guidelines, which require documented weight history, comorbidity assessment, contraindication screening (personal or family history of medullary thyroid carcinoma or MEN2), and a discussion of expected titration schedules. [4] Any telehealth platform's quality can be partially benchmarked against whether these steps appear in the patient intake flow.

Is Mochi Health Legit? Regulatory and Accreditation Signals

"Legit" means different things in different contexts. From a regulatory standpoint, a telehealth prescribing platform is legitimate if its prescribers hold valid state licenses, if it dispenses through licensed pharmacies, and if it prescribes within FDA-approved indications or documents a valid clinical rationale for off-label use.

State Medical Board and Pharmacy Licensing

Telehealth prescribing across state lines requires that the prescribing provider hold a license in the patient's state of residence, per the Ryan Haight Online Pharmacy Consumer Protection Act and subsequent DEA telehealth rules. [5] Patients can verify their assigned provider's license through their state medical board. Mochi Health uses a network of licensed providers, but the company does not publish a full roster, which makes independent verification difficult.

Compounded drugs must originate from a pharmacy registered with the FDA as a 503B outsourcing facility or from a state-licensed 503A compounding pharmacy with a valid patient-specific prescription. The FDA maintains a public database of registered 503B facilities. [6] Patients receiving compounded GLP-1 medications from Mochi Health should confirm the originating pharmacy appears on that registry.

BBB Complaint Data

The Better Business Bureau (BBB) complaint record is a consumer-facing signal, not a clinical one, but it reflects billing, fulfillment, and customer-service failures that can indicate systemic operational problems. As of January 2025, Mochi Health is not BBB-accredited and has accumulated complaints in categories including billing disputes, difficulty canceling subscriptions, and delayed medication shipments. These complaint types are consistent with patterns seen across multiple GLP-1 telehealth platforms and do not by themselves indicate unsafe prescribing. They do suggest that operational oversight may lag clinical oversight.

LegitScript Status

LegitScript is the verification authority used by Google, Meta, and other ad platforms to certify online pharmacies and telehealth companies. LegitScript certification requires compliance with applicable laws, a valid pharmacy license, and prescribing by licensed practitioners. Mochi Health's LegitScript status should be verified directly at legitscript.com before drawing conclusions, as certification status can change. Platforms advertising prescription drugs without LegitScript certification on major ad networks are in violation of those platforms' policies, which is itself a red flag.

GLP-1 Outcomes Benchmarks: What to Expect From Any Prescriber

No telehealth platform, including Mochi Health, has published peer-reviewed outcomes data from its own patient population. That absence is itself informative. The clinical trials that support GLP-1 prescribing set clear benchmarks that any prescriber's patient outcomes should approach if prescribing and adherence support are done well.

The STEP and SURMOUNT Trial Benchmarks

STEP-1 (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body-weight loss at 68 weeks versus 2.4% with placebo. [2] STEP-4 demonstrated that discontinuing semaglutide after 20 weeks led to weight regain of approximately 6.9 percentage points by week 68, reinforcing that GLP-1 therapy requires continuity, not a short course. [7]

For tirzepatide, SURMOUNT-1 (N=2,539) showed 15 mg weekly produced 20.9% mean weight reduction at 72 weeks, with 57% of participants achieving at least 20% weight loss. [8] These figures come from controlled trial settings with close monitoring. Real-world adherence rates are lower. A 2023 analysis published in JAMA Network Open found that 12-month persistence with GLP-1 therapy in commercial insurance claims was approximately 44%, meaning more than half of patients discontinued within one year. [9]

What Outcomes Signals Mochi Health Has Released Publicly

Mochi Health has cited internal marketing claims of significant average weight loss across its patient base, but these figures are not published in peer-reviewed literature, are not adjusted for dropout, and cannot be independently verified. The absence of a published outcomes registry or a partnership with an academic center for outcomes tracking is a gap that applies to most GLP-1 telehealth companies, not just Mochi Health. Patients should ask any telehealth provider: what is your 12-month retention rate, and what percentage of active patients achieve at least 5% body-weight reduction, which is the minimum threshold the FDA uses to define a meaningful clinical response. [1]

The framework below represents the HealthRX standard for evaluating any GLP-1 telehealth platform's outcomes claims:

1. Is the sample complete (all enrollees) or only completers?
2. Is follow-up duration at least 52 weeks?
3. Is there a comparison group or adjustment for regression to the mean?
4. Has the data been reviewed by an independent statistician?
5. Is the pharmacy fulfillment rate (drug actually dispensed vs. Prescribed) reported separately?

Compounded GLP-1 Medications: The Specific Risk Mochi Health Patients Face

This section applies to any platform that dispensed or continues to dispense compounded semaglutide or tirzepatide. The FDA has issued multiple safety communications on this topic.

FDA Shortage Declarations and Compounding Windows

During a declared drug shortage, Section 503A and 503B compounders can legally prepare copies of shortage-listed drugs. The FDA added semaglutide to the shortage list in 2022 and tirzepatide in 2023. [3] The semaglutide shortage was declared resolved in October 2024, which means 503B facilities had a wind-down period before they were required to stop compounding. 503A pharmacies, which compound on a patient-specific basis, face a shorter compliance window.

Platforms that continued fulfilling compounded semaglutide orders past the compliance date are potentially violating federal law, and patients receiving those shipments could be receiving an unapproved drug. The FDA has received adverse event reports associated with compounded semaglutide, including dosing errors linked to high-concentration formulations. [3]

Salt vs. Base Form Compounding

A specific technical risk involves compounding with semaglutide sodium or acetate salts rather than semaglutide base. The FDA has explicitly stated that compounding with these salt forms is not permissible because they are not the same as the approved active ingredient. [3] Patients should ask their Mochi Health (or any platform) pharmacy to confirm in writing which form of semaglutide is in their compounded product.

Mochi Health Complaints: Patterns in Consumer Reports

Consumer complaints about Mochi Health cluster in a few categories that appear across multiple review platforms including Trustpilot, Reddit threads, and the BBB complaint portal. A systematic reading of these complaints identifies the following patterns.

Billing and Subscription Issues

The most common complaint category involves difficulty canceling subscriptions and unexpected charges after patients believed they had canceled. This pattern does not speak to prescribing quality but does indicate that the platform's billing infrastructure may not match its clinical aspirations. The FTC's "click-to-cancel" rule, finalized in October 2024, requires that cancellation be as easy as enrollment. [10] Persistent billing complaints after that rule's effective date would represent a compliance problem.

Medication Fulfillment Delays

A second complaint category involves extended delays between prescription issuance and medication shipment, particularly for compounded GLP-1 products. Delays of four to eight weeks appear in multiple accounts. From a clinical standpoint, gaps in GLP-1 therapy cause partial loss of receptor downregulation effect and can require re-titration, which prolongs the time to therapeutic dose. The STEP-4 trial data on weight regain after discontinuation provides a quantitative proxy for the cost of these gaps. [7]

Provider Continuity Concerns

A smaller but notable complaint category involves patients being reassigned to different providers without notice, making it difficult to maintain a longitudinal treatment relationship. Obesity medicine best practice, as outlined by the Obesity Medicine Association, emphasizes ongoing provider-patient relationships for dose adjustment, side-effect management, and behavioral support. [11] Frequent provider changes undermine that model.

How Mochi Health Compares to FDA-Approved Prescribing Standards

The FDA approval of semaglutide 2.4 mg (Wegovy) and tirzepatide 15 mg (Zepbound) came with Risk Evaluation and Mitigation Strategies (REMS) requirements for certain scenarios and explicit label language requiring adjunct lifestyle intervention. [1] The label states: "Wegovy should be used in conjunction with a reduced-calorie diet and increased physical activity." Whether telehealth platforms systematically deliver that adjunct support is not auditable from the outside.

The AACE Guideline Standard for Telehealth Prescribing

The 2023 AACE Obesity CPG states that pharmacotherapy for obesity should be initiated by a clinician with training in obesity medicine or endocrinology, or with access to consultation. [4] The guideline also specifies that medication choice should account for comorbidities: semaglutide has cardiovascular outcome data from SUSTAIN-6 (N=3,297), which showed a 26% reduction in major adverse cardiovascular events versus placebo in patients with type 2 diabetes and high CV risk (hazard ratio 0.74, 95% CI 0.58 to 0.95). [12] A platform prescribing GLP-1 agents to patients with cardiovascular disease should be selecting the agent with the best CV outcome data, not simply the cheapest compounded option.

The SELECT Trial and Cardiovascular Indication

In August 2024, the FDA approved semaglutide 2.4 mg for reduction of cardiovascular risk in adults with obesity or overweight and established cardiovascular disease, based on the SELECT trial (N=17,604), which showed a 20% reduction in major adverse cardiovascular events versus placebo (hazard ratio 0.80, 95% CI 0.72 to 0.90, P<0.001). [13] A prescribing platform handling high-risk cardiovascular patients should be documenting this indication specifically, and coordinating with the patient's cardiologist. There is no public evidence that Mochi Health has a structured protocol for this patient subgroup.

What Patients Should Ask Before Starting With Any GLP-1 Telehealth Platform

The quality signals that matter are not brand name, marketing claims, or price. The following questions produce the most diagnostic information about whether a platform will deliver safe, effective, guideline-aligned GLP-1 care.

Clinical Quality Questions

Ask whether the prescribing provider holds a current medical license in your state. Ask whether the provider has completed any obesity medicine training or holds a certification from the American Board of Obesity Medicine (ABOM). Ask what the dose titration schedule is and whether there is a protocol for managing common side effects like nausea, vomiting, and gastroparesis. GLP-1 receptor agonists carry a class warning for gastroparesis and ileus; a 2023 case-control study in JAMA (N=4,144 GLP-1 users) found a 3.67-fold increased risk of gastroparesis compared to bupropion-naltrexone users (adjusted odds ratio 3.67, 95% CI 1.15 to 11.90). [14]

Pharmacy and Formulation Questions

Ask whether your medication is coming from an FDA-registered 503B outsourcing facility. Ask specifically whether any compounded semaglutide contains semaglutide base (not a salt form). Ask for the lot number and certificate of analysis for any compounded product. These requests are reasonable and any reputable compounding pharmacy will fulfill them.

Outcomes Transparency Questions

Ask the platform what percentage of its active patients achieve at least 5% weight loss at 12 months. Ask what the platform's 12-month medication persistence rate is. If the platform cannot or will not answer these questions, treat that as a material signal about the quality of its outcomes tracking.

The Bottom Line on Mochi Health's Prescribing Quality

Mochi Health operates within a legal framework that permits telehealth GLP-1 prescribing, and the drugs it prescribes, when FDA-approved and properly dosed, have strong clinical evidence behind them. The platform's weaknesses, based on available public data, are: lack of published outcomes data, unresolved consumer complaints around billing and fulfillment, potential exposure to post-shortage compounding compliance questions, and no documented protocol for high-risk subgroups like patients with established cardiovascular disease.

None of these weaknesses are unique to Mochi Health. They are sector-wide problems in the GLP-1 telehealth space. The standard of care is set by the clinical trials and the AACE, FDA, and Obesity Medicine Association guidelines, not by what any individual platform claims internally. The SELECT trial result of a 20% cardiovascular event reduction with semaglutide 2.4 mg represents the current ceiling of evidence for this drug class. Patients deserve a prescribing relationship that reaches toward that ceiling, not one that stops at fulfillment.